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Eur J Vasc Endovasc Surg (2015) 49, 676e677EDITORIALManaging Chronic Venous Disease: An Ongoing ChallengeIn this issue of the Journal, the European Society for
Vascular Surgery (ESVS) Guidelines on the management of
chronic venous disease (CVD) are published.1 These guide-
lines differ from those prepared by the Society for Vascular
Surgery and the American Venous Forum2 as they include
CVD associated with deep venous obstruction/incompe-
tence and venous malformations. Although considerable
progress has been made since the publication of the very
ﬁrst randomized clinical trial on the treatment of varicose
veins,3 there is still a lack of published high-quality evidence
in many ﬁelds of CVD management.
The underlying pathophysiology of CVD and progression
of disease with time are poorly understood, making the
planning of CVD management more difﬁcult, particularly
when trying to answer the question: Which patients should
be treated and when? Some issues, such as a history of
recurrent deep vein thrombosis, the presence of atrophie
blanche or lipodermatosclerosis (C4b, according to the
CEAP classiﬁcation4), and/or axial reﬂux from the groin to
the ankle using duplex ultrasound (DUS), clearly predict an
unfavourable prognosis leading to an increased risk of
venous ulceration. In this subgroup of patients, the indica-
tion for treatment is clear-cut. However, there are other
areas of practice in the ﬁeld of CVD management which
remain “grey areas”, such as the large group of patients with
symptomatic varicose veins, which are classiﬁed as C2S (or
C2,3S) Ep As Pr with reﬂux of the great saphenous vein
(GSV). In the latest ESVS guidelines, there is a Class I, Level
A recommendation for endovenous thermal ablation of the
reﬂuxing GSV1; however, an alternative approach consisting
of phlebectomies only (without treatment of the GSV),
might be equally effective.5,6 For advocates of the latter
approach, evidence from randomized trials is still awaited.
In addition, DUS-related predictive factors, which will be
helpful for proper patient selection, require further
investigation.
The optimal management of recurrent varicose veins is
another grey area, as it usually has a multi-factorial aeti-
ology, leading to a variety of clinical manifestations and DUS
ﬁndings.7 In the latest ESVS guidelines, extensive redo
varicose vein surgery is no longer recommended as the ﬁrst-
line treatment strategy1 and minimally invasive in-
terventions are now the preferred option. In practice, after
carefully studying DUS anatomy and haemodynamics, anDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2015.02.007.
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http://dx.doi.org/10.1016/j.ejvs.2015.02.014individual patient-tailored treatment is required. This may
involve a combination of phlebectomies, thermal (or non-
thermal) ablation of a residual reﬂuxing saphenous trunk,
and/or ultrasound-guided foam sclerotherapy.8 These man-
agement strategies still require to be evaluated in carefully
performed, prospective studies, which should include long-
term follow-up and an assessment of quality of life.
Another grey area of modern practice relates to the
treatment of patients who have CVD secondary to chronic
(mainly post-thrombotic) changes in the deep venous sys-
tem. It remains to be seen how clinicians can identify which
patients have “clinically relevant” deep venous lesions (as is
cited in the ESVS guidelines1) and who might therefore be
potential candidates for venous stenting. A number of key
issues will need to be addressed in future guidelines. Firstly,
the clinical diagnosis of post-thrombotic syndrome (PTS)
needs to be better deﬁned. For example, venous claudica-
tion, a common and important clinical feature in PTS pa-
tients with chronic iliofemoral or iliocaval obstruction, is not
included within the venous clinical severity score9 or in the
Villalta scale,10 although the latter was speciﬁcally designed
for scoring PTS. Second, the correlation between symp-
toms/signs of CVD and haemodynamic measurements
require careful study. Combining quantitative measure-
ments of reﬂux and outﬂow resistance (resulting from the
impact of obstruction and the adequacy of collateral cir-
culation), may increase the understanding of PTS in indi-
vidual patients.11 In addition, new deep venous imaging
techniques, and new stent materials require further evalu-
ation. Finally, as potential candidates for venous stenting
are usually quite young, it is important that future studies
report long-term outcomes in order to assess overall
beneﬁt.
Venous ulcer patients still represent a signiﬁcant socio-
economic burden. Accordingly, the ﬁnal goal of manage-
ment should be to reduce the prevalence of venous ulcer-
ation in the general population. While compression therapy
remains the cornerstone of ﬁrst-line treatment, the ESVS
guidelines recommend “active venous intervention” to
reduce ulcer recurrence.1 Apart from correction of super-
ﬁcial venous incompetence, this should also include treat-
ment of deep venous obstruction12 and/or reﬂux. More
prospective studies are required to evaluate the results of
deep venous interventions in ulcer patients.
Finally, in an era where health-care resources are
increasingly limited, it is of the utmost importance to be
able to make proper treatment choices13 while simulta-
neously optimizing cost-effectiveness.14 In order to achieve
this balance, more basic research is required to better
Editorial 677understand venous haemodynamics and pathophysiology.
Changes in the vein wall (not only in varicose veins but also
in post-thrombotic veins), the function (and dysfunction) of
macroscopic valves15 and the potential role of micro-
valves,16 the importance of the calf and foot pump,17 and
ﬁnally the natural progression of CVD over time18 require
detailed evaluation.
The latest ESVS guidelines represent a detailed summary
of what we currently know. Improving knowledge, opti-
mizing investigative strategies and delivering high-quality
care represents an ongoing challenge, but it looks like
‘the best is yet to come’.
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